# Cross-session log — dapagliflozin-cardiorenal-2026

Maintained by: dapa-research-director [01c492]

## 2026-08-27 — Cross-session health check (CROSS_SESSION_TEST)

Director session: `dapa-research-director [01c492]`
Method: ListAgents discovery + standardized PING to each required peer.
No local substitute subagents were created.

| Peer | Ref | Reply | CWD | Branch | State at reply |
|---|---|---|---|---|---|
| dapa-landmark-evidence | 8f99d0 | PONG / READY | project root | main | Executing 01_LANDMARK.md; in place (unborn HEAD blocked worktree) |
| dapa-frontier-evidence | 812bcc | READY | project root | main | Executing 02_FRONTIER.md; will isolate to worktree before writing |
| dapa-safety-implementation | df2cdb | READY | project root | main | Beginning 03_SAFETY.md |
| dapa-methods-auditor | 3f675f | PONG / READY | project root | main | Holding until first-wave outputs exist |

Result: 4/4 peers reachable. Health check PASSED.

## 2026-08-27 — Baseline commit

Repository had an unborn HEAD (zero commits), which blocked worktree
creation and left peers on divergent write strategies.

Director committed baseline `6a4ebda` on `main`: CLAUDE.md,
protocol/SEARCH_PROTOCOL.md, prompts/01–04, source question document.
Worktree isolation is now possible; all peer commits share this ancestor.

## 2026-08-27 — Evidence gate check: NOT MET

- dapa-methods-auditor reported BLOCKED_MISSING_INPUTS: none of the seven
  first-wave input files exist. Director independently verified:
  `evidence/**` and `appraisal/` contain zero files; the only commit on any
  branch is baseline `6a4ebda`.
- Synthesis, claims ledger, and talk drafting are therefore ON HOLD.
  No outputs will be fabricated ahead of committed peer evidence.
- Directive sent to Landmark, Frontier, Safety: write durable outputs to
  owned paths, commit, and report exact paths + commit hash to the Director.
  Auditor to receive READY_FOR_AUDIT with covering hashes once all three land.

### Path ownership (restated)

- dapa-landmark-evidence: `evidence/landmark/`, `evidence/guidelines-labels/`
- dapa-frontier-evidence: `evidence/frontier/`
- dapa-safety-implementation: `evidence/safety/`
- dapa-methods-auditor: `appraisal/`
- Director: `synthesis/`, `talk/`, `logs/CROSS_SESSION_LOG.md`

## 2026-08-27 — Remote, first-wave completion, integration

- Director added remote github.com/zinojeng/dapagliflozin (user authorization)
  and pushed main plus all peer branches.
- First-wave peer commits, each verified by the Director before acceptance:
  - frontier `5d49653` (4 files) — accepted pending audit
  - landmark `380155f` (4 files incl. citation-verification log) — accepted pending audit
  - safety `d1607f6` (4 files + sources/ with 16 primary regulatory documents) — accepted pending audit
- Director merged all branches into `main` → `b7322d4`, pushed.
- READY_FOR_AUDIT sent to dapa-methods-auditor with covering hashes and
  prioritized peer flags (DECLARE safety-table PMC-reproduction sourcing;
  DARE-ESKD-2 CI/P discordance; care-spectrum meta identity; ⚠️FT/⚠️TW registers).
- Director launched five temporary fulltext-fetcher subagents (landmark trials,
  acute-HF set, MI/TAVI, advanced kidney, guidelines/labels) targeting 原始PDF/
  with LlamaParse conversion; manifests pending. These are internal temps, not
  substitute peers.

## 2026-08-27 — Director reading pass and reconciliation items

- All 12 first-wave files read in full by the Director.
- RECONCILIATION-1 sent to safety: DAPA-HF diabetes proportion — safety matrix
  wrote 45% without diabetes; Petrie 2020 (PMID 32219386) gives 2,605/4,744 = 55%
  without diabetes. Correction requested (single cell).
- Frontier care-spectrum meta-analysis identity: peers found no distinct
  dapagliflozin-specific DAPA-HF+DELIVER+DAPA ACT HF pooled paper; source-doc
  claim stays flagged; fetch-acutehf running a targeted search; auditor to adjudicate.
- Landmark ⚠️FT items (5) await 原始PDF/ full texts; landmark standing by to close
  them in a follow-up commit.

## 2026-08-27/28 — Audit cycle, fulltext landing, second-round closures

- Methods audit complete (1f2eafa): 31-claim ledger, 20 overclaim red lines
  (O-1..O-20, adopted as binding via DECISION_LOG D18), pending register P-1..P-10.
  All four Director priority flags resolved. Auditor + safety sessions went
  offline afterward; their committed work is integrated. Pending handoff for
  relaunched auditor: amend CONTRADICTIONS §1.2 (care-spectrum meta exists),
  re-verify P-8 fix (d20a618), run P-1..P-7 second round when NEJM PDFs land.
- Reconciliation fixes integrated: safety d20a618 (DAPA-HF 55% without diabetes);
  frontier c6a2f8c (P-9 denominators, registry-verified ONGOING items, INFINITI
  2026 anchoring) + 72bfa41 (care-spectrum amendment).
- D4 REVERSED: care-spectrum meta EXISTS — Berg et al. JACC Heart Fail
  2026;14(8):103232, PMID 42547169, published 2026-08-01, unindexed/paywalled;
  cite existence only, zero numbers. Independently re-verified by frontier.
- Fulltext landing: 14 verified documents in 原始PDF/ (pdftotext fallback;
  LlamaParse credits exhausted). 10 targets unobtainable (MISSING_FULLTEXT.md),
  incl. all four NEJM primaries — landmark fetch agent lost to session limit,
  Sci-Hub MCP broken (missing Playwright browser). Six polluted substitute
  downloads caught and deleted by fetcher eyeball checks.
- Director synthesis layer shipped: DECISION_LOG (20 rulings), CLAIMS_LEDGER
  (28 claims), MASTER_SYNTHESIS (+topic ranking), CONTROVERSIES (9),
  EVIDENCE_GAPS (14), CLINICAL_QA (22 questions, landmark-weighted per user
  directive). Talk package shipped: TALK_OUTLINE (40 min, 25 slides,
  NOT-proven slide), CLINICAL_CASES (4), MODERATOR_QUESTIONS (10).
- Landmark second round ed8dae6: FT #4/#5 closed with verbatim locators
  (KDIGO 3.7.1–3.7.3 numbering corrected); FDA s035 (rev 06/2026) confirmed
  controlling — new affirmative continuation-below-eGFR-25 clause (§2.3) and
  PKD limitation-of-use (§1) adopted into synthesis; D16 closed.
- Integrations pushed: main b7322d4 → 3672015 → d57fe99 (github.com/zinojeng/
  dapagliflozin). Open: FT #1–3/#6 + auditor P-1..P-7 blocked on the four
  NEJM primary PDFs (user upload needed); Berg care-spectrum full text for
  frontier number-extraction when obtainable.

## 2026-08-28 — Empagliflozin-vs-dapagliflozin comparison (Workflow run)

- User directive: research empa-vs-dapa differences and clinical impact via
  cross-session peers or workflow. All four dapa peer sessions were offline
  (ListAgents), so the work ran as a Workflow (user-authorized): 5 parallel
  domain research agents (trial architecture, pharmacology/labels,
  head-to-head, guidelines/Taiwan, safety) each piped into an independent
  citation-verification agent. 10 agents, 339 tool calls, 83 claims — 73
  verified exactly against PubMed/Crossref/DailyMed/ClinicalTrials.gov;
  10 flags with corrections, all applied. No substitute peer sessions created.
- Key verified findings: no head-to-head outcome RCT (first: APPLE TREE
  NCT06642272, n≈17,200, completes 2028-12); best observational evidence
  (Scandinavian registry n=199k, OHDSI 10-database, Korean echo-LVEF cohort)
  and NMAs all null; real differences = evidence-base coverage (EMPA-KIDNEY
  non-albuminuric/eGFR≥20 vs DAPA-CKD albuminuric/≥25), label wording
  (CV-death vs HHF claims; eGFR floors), Taiwan NHI joint entry (identical
  criteria), cost (dapagliflozin UK patent invalidated 2025).
- Outputs committed: evidence/comparison/EMPA_DAPA_EVIDENCE_MATRIX.md (new
  Director-owned path, D21), synthesis/EMPA_VS_DAPA.md (Traditional Chinese,
  red lines O-21..O-26, D22). Pending: offline methods auditor to re-audit
  both files on relaunch.
